CL2007002026A1 - Composicion que comprende al menos un compuesto quelante de hierro y al menos un agente antifungico; y metodo para el tratamiento o prevencion de una condicion fungica. - Google Patents

Composicion que comprende al menos un compuesto quelante de hierro y al menos un agente antifungico; y metodo para el tratamiento o prevencion de una condicion fungica.

Info

Publication number
CL2007002026A1
CL2007002026A1 CL200702026A CL2007002026A CL2007002026A1 CL 2007002026 A1 CL2007002026 A1 CL 2007002026A1 CL 200702026 A CL200702026 A CL 200702026A CL 2007002026 A CL2007002026 A CL 2007002026A CL 2007002026 A1 CL2007002026 A1 CL 2007002026A1
Authority
CL
Chile
Prior art keywords
fungical
ironing
prevention
treatment
composition
Prior art date
Application number
CL200702026A
Other languages
English (en)
Spanish (es)
Inventor
Brad J Spellberg
John E Edwards
Ashraf S Ibrahim
Original Assignee
Los Angeles Biomed Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Biomed Res Inst filed Critical Los Angeles Biomed Res Inst
Publication of CL2007002026A1 publication Critical patent/CL2007002026A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL200702026A 2006-07-13 2007-07-12 Composicion que comprende al menos un compuesto quelante de hierro y al menos un agente antifungico; y metodo para el tratamiento o prevencion de una condicion fungica. CL2007002026A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83109906P 2006-07-13 2006-07-13
US89762007P 2007-01-26 2007-01-26
US90407507P 2007-02-27 2007-02-27

Publications (1)

Publication Number Publication Date
CL2007002026A1 true CL2007002026A1 (es) 2008-06-06

Family

ID=38610625

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200702026A CL2007002026A1 (es) 2006-07-13 2007-07-12 Composicion que comprende al menos un compuesto quelante de hierro y al menos un agente antifungico; y metodo para el tratamiento o prevencion de una condicion fungica.

Country Status (18)

Country Link
US (1) US20100129434A1 (enExample)
EP (2) EP2043636A2 (enExample)
JP (2) JP2009543788A (enExample)
KR (1) KR20090036587A (enExample)
AU (1) AU2007272781B2 (enExample)
BR (1) BRPI0714221A2 (enExample)
CA (1) CA2657634A1 (enExample)
CL (1) CL2007002026A1 (enExample)
IL (1) IL196389A0 (enExample)
MA (1) MA30625B1 (enExample)
MX (1) MX2009000506A (enExample)
NO (1) NO20090565L (enExample)
NZ (1) NZ574862A (enExample)
RU (1) RU2464024C2 (enExample)
SG (1) SG177122A1 (enExample)
TN (1) TN2009000004A1 (enExample)
TW (1) TWI448285B (enExample)
WO (1) WO2008008537A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2755273A1 (en) * 2009-03-19 2010-09-23 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases
US8980876B2 (en) 2010-10-28 2015-03-17 The Procter & Gamble Company Inhibition of microbial growth by aconitase inhibition
US20150246027A1 (en) * 2012-11-12 2015-09-03 Cipla Limited Fixed dose pharmaceutical composition comprising deferasirox and deferiprone
US11229685B2 (en) 2013-01-29 2022-01-25 Case Western Reserve University Fungal iron acquisition inhibitors and uses thereof
US20160199361A1 (en) * 2013-08-19 2016-07-14 Rutgers, The State University Of New Jersey Method of Inducing An Anti-Retroviral Immune Response By Counter-Acting Retro-Virus Induced Anti-Apoptosis
WO2016025611A2 (en) * 2014-08-13 2016-02-18 Zoneone Pharma, Inc. Pharmaceutical formulations of chelating agents as a metal removal treatment system
WO2016025559A1 (en) * 2014-08-13 2016-02-18 Zoneone Pharma, Inc. Pharmaceutical formulations of and methods to prepare chelating agents for efficient metal removal treatment systems
US11298364B2 (en) * 2015-08-31 2022-04-12 The University Of Adelaide Methods and products for preventing and/or treating microorganism infections comprising iron chelators and non-iron porphyrins
US10960002B2 (en) 2016-05-13 2021-03-30 The Brigham And Women's Hospital, Inc. Volatile metabolite profiles for the diagnosis and treatment of Mucorales fungi
FR3095755A1 (fr) * 2019-05-10 2020-11-13 Balmes Transplantation Nouveaux médicaments cytoprotecteurs
CN113905715B (zh) 2019-06-28 2025-04-15 宝洁公司 光增强处理方法
JP2023057423A (ja) * 2021-10-11 2023-04-21 国立大学法人 熊本大学 ムコール症治療薬

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8329043D0 (en) * 1983-10-31 1983-11-30 Hider R C Pharmaceutical compositions
US4698431A (en) * 1985-11-12 1987-10-06 The United States Of America As Represented By The United States Department Of Energy Hydroxypyridonate chelating agents
PH31594A (en) * 1993-09-30 1998-11-03 Janssen Pharmaceutica Nv Oral formulations on an antifungal.
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
WO1999009997A1 (en) * 1997-08-26 1999-03-04 Board Of Regents, The University Of Texas System Edta and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
DE50111949D1 (de) * 2000-12-16 2007-03-15 Alstom Technology Ltd Komponente einer Strömungsmaschine
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
ITMI20022447A1 (it) * 2002-11-19 2004-05-20 Carlo Ghisalberti Uso di piridinoni nel trattamento della purpura capillare ed affezioni cutanee correlate.
AU2003302274A1 (en) * 2002-12-31 2004-07-29 Novartis Ag Aerosolizable pharmaceutical formulation for fungal infection therapy
WO2004108114A2 (en) * 2003-03-31 2004-12-16 Dinesh Shantilal Patel Anti-fungal composition and a process for its manufacture
DE10356409B4 (de) * 2003-11-28 2006-12-28 Biofrontera Discovery Gmbh Neues Arzneimittel Oxachelin und Derivate

Also Published As

Publication number Publication date
AU2007272781A1 (en) 2008-01-17
TW200816994A (en) 2008-04-16
MX2009000506A (es) 2009-05-20
BRPI0714221A2 (pt) 2013-01-01
WO2008008537A2 (en) 2008-01-17
MA30625B1 (fr) 2009-08-03
JP2009543788A (ja) 2009-12-10
KR20090036587A (ko) 2009-04-14
EP2043636A2 (en) 2009-04-08
CA2657634A1 (en) 2008-01-17
TWI448285B (zh) 2014-08-11
IL196389A0 (en) 2009-09-22
AU2007272781B2 (en) 2012-10-18
RU2464024C2 (ru) 2012-10-20
NO20090565L (no) 2009-03-30
JP2013040212A (ja) 2013-02-28
EP2412371A1 (en) 2012-02-01
US20100129434A1 (en) 2010-05-27
SG177122A1 (en) 2012-01-30
WO2008008537A3 (en) 2008-04-24
TN2009000004A1 (en) 2010-08-19
NZ574862A (en) 2012-02-24
RU2009104961A (ru) 2010-08-20

Similar Documents

Publication Publication Date Title
CL2007002026A1 (es) Composicion que comprende al menos un compuesto quelante de hierro y al menos un agente antifungico; y metodo para el tratamiento o prevencion de una condicion fungica.
CL2009000130A1 (es) Compuestos derivados de 5-fluoro-pirimidina; composicion fungicida que comprende a dichos compuestos; y metodo para el control o prevencion de un ataque fungico a una planta.
CL2007003138A1 (es) Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2009000647A1 (es) Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
CL2007003722A1 (es) Compuestos derivados de propionamida n-sustituida por heterociclo, activadores de glucoquinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento o prevencion de la diabetes.
HN2006000971A (es) Metodos para preparar composiciones o formas de dosificacion que comprenden un agonista grp119 que tiene el efecto de un secretagogo glp-1
CL2008003653A1 (es) Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
CL2007002234A1 (es) Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
CL2007002916A1 (es) Compuestos derivados de pirazoliltienopiridinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en la inhibicion de escaras.
CL2007003299A1 (es) Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CL2007001992A1 (es) Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege
CL2007003743A1 (es) Composicion que comprende fenamidona y un compuesto insecticida; y metodo para controlar de forma curativa o preventiva hongos fitopatogenos de cultivos e insectos.
CL2007003540A1 (es) Compuestos derivados de macrociclos, inhibidores de la proteasa serina de hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
SV2009002899A (es) Diarilureas para el tratamiento de la hipertension pulmonar
CL2007003244A1 (es) Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
BRPI0717753A2 (pt) Método de tratamento ou redução do risco de uma doença causada por protozoários, e, composição.
CL2010001361A1 (es) Compuestos derivados de piperidin-carboxamida, inhibidores de renina; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de una enfermedad circulatoria, hipertension y/o diversos daños organicos atribuibles a la hipertension.
WO2008070129A3 (en) Compositions and methods for the treatment of inflammatory disease
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
CL2007003331A1 (es) Metodo para tratar cancer mediante la administracion de un agente radiosensibilizante derivado de benzo[a]trinden-4,6-diona; composicion farmaceutica que comprende dicho agente.
GT200900065A (es) Derivado de 2-piridincarboxamida que tiene efecto activador de gk
CL2007002479A1 (es) Compuestos derivados de pirazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos tromboembolicos.
CL2007003587A1 (es) Compuestos derivados de pirimidinas sustituidas; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para tratar o prevenir la infeccion de la hepatitis c.
CL2004001004A1 (es) Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple.
CL2007003847A1 (es) Compuestos derivados de pirimidinas 2,4,5 tri-sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del cancer.